Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells

Trastuzumab has been widely used for the treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer, however, it cannot easily cross the blood-brain barrier (BBB) and is known to increase the incidence of brain metastases. In contrast, lapatinib has a low molecular wei...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Tosol, Cho, Bong Jun, Choi, Eun Jung, Park, Ji Min, Kim, Dan Hyo, Kim, In Ah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346700/
https://www.ncbi.nlm.nih.gov/pubmed/27738326
http://dx.doi.org/10.18632/oncotarget.12597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346700/
https://www.ncbi.nlm.nih.gov/pubmed/27738326
http://dx.doi.org/10.18632/oncotarget.12597

Ejemplares similares